{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T08:21:12Z","timestamp":1778401272907,"version":"3.51.4"},"reference-count":72,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.3816\/clm.2007.n.011","type":"journal-article","created":{"date-parts":[[2008,9,11]],"date-time":"2008-09-11T01:11:07Z","timestamp":1221095467000},"page":"346-353","source":"Crossref","is-referenced-by-count":23,"title":["Clinical Utility of Biochemical Markers of Bone Metabolism for Improving the Management of Patients with Advanced Multiple Myeloma"],"prefix":"10.3816","volume":"7","author":[{"given":"Allan","family":"Lipton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert E.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Major","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Berenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl 4","key":"10.3816\/CLM.2007.n.011_bib1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.9-90004-14","article-title":"Bisphosphonates: clinical experience","volume":"9","author":"Coleman","year":"2004","journal-title":"Oncologist"},{"key":"10.3816\/CLM.2007.n.011_bib2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1172\/JCI115305","article-title":"Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma","volume":"88","author":"Bataille","year":"1991","journal-title":"J Clin Invest"},{"key":"10.3816\/CLM.2007.n.011_bib3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/8756-3282(94)90890-7","article-title":"Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma","volume":"15","author":"Roux","year":"1994","journal-title":"Bone"},{"key":"10.3816\/CLM.2007.n.011_bib4","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1600-0609.1992.tb00046.x","article-title":"Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption","volume":"49","author":"Taube","year":"1992","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLM.2007.n.011_bib5","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2141.1982.tb03936.x","article-title":"Quantitative histology of myeloma-induced bone changes","volume":"52","author":"Valentin-Opran","year":"1982","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2007.n.011_bib6","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2001.19.15.3562","article-title":"Biology of osteoclast activation in cancer","volume":"19","author":"Roodman","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.n.011_bib7","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1365-2141.2004.04864.x","article-title":"Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma","volume":"125","author":"Hashimoto","year":"2004","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2007.n.011_bib8","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1210\/en.139.11.4743","article-title":"Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells","volume":"139","author":"Horwood","year":"1998","journal-title":"Endocrinology"},{"key":"10.3816\/CLM.2007.n.011_bib9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"10.3816\/CLM.2007.n.011_bib10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"10.3816\/CLM.2007.n.011_bib11","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1182\/blood.V98.13.3527","article-title":"Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment","volume":"98","author":"Giuliani","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.n.011_bib12","doi-asserted-by":"crossref","first-page":"11581","DOI":"10.1073\/pnas.201394498","article-title":"Multiple myeloma disrupts the TRANCE\/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression","volume":"98","author":"Pearse","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3816\/CLM.2007.n.011_bib13","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood.V98.7.2269","article-title":"Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease","volume":"98","author":"Seidel","year":"2001","journal-title":"Blood"},{"issue":"16 suppl","key":"10.3816\/CLM.2007.n.011_bib14","first-page":"585s","article-title":"Biochemical markers of bone turnover in the diagnosis of myeloma bone disease","volume":"23","author":"Dizdar","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.n.011_bib15","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1365-2141.2004.05092.x","article-title":"Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS)","volume":"126","author":"Politou","year":"2004","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2007.n.011_bib16","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.1210\/jc.2003-030910","article-title":"Clinical review 165: markers of bone remodeling in metastatic bone disease","volume":"88","author":"Fohr","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.3816\/CLM.2007.n.011_bib17","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1359\/jbmr.1999.14.5.792","article-title":"Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices","volume":"14","author":"Woitge","year":"1999","journal-title":"J Bone Miner Res"},{"key":"10.3816\/CLM.2007.n.011_bib18","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1002\/cncr.10522","article-title":"The clinical use of bone resorption markers in patients with malignant bone disease","volume":"94","author":"Coleman","year":"2002","journal-title":"Cancer"},{"key":"10.3816\/CLM.2007.n.011_bib19","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/jbmr.5650060615","article-title":"Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis","volume":"6","author":"Delmas","year":"1991","journal-title":"J Bone Miner Res"},{"issue":"suppl","key":"10.3816\/CLM.2007.n.011_bib20","doi-asserted-by":"crossref","first-page":"17S","DOI":"10.1097\/00007632-199712151-00004","article-title":"Bone biomarkers as tools in osteoporosis management","volume":"22","author":"Eyre","year":"1997","journal-title":"Spine"},{"key":"10.3816\/CLM.2007.n.011_bib21","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1042\/bj2520495","article-title":"Collagen cross-linking in human bone and articular cartilage. Age-related changes in the content of mature hydroxypyridinium residues","volume":"252","author":"Eyre","year":"1988","journal-title":"Biochem J"},{"key":"10.3816\/CLM.2007.n.011_bib22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S8756-3282(97)00279-2","article-title":"Collagen cross-links in mineralizing tissues: a review of their chemistry, function, and clinical relevance","volume":"22","author":"Knott","year":"1998","journal-title":"Bone"},{"key":"10.3816\/CLM.2007.n.011_bib23","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0305-7372(96)90021-3","article-title":"Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment","volume":"22","author":"Vinholes","year":"1996","journal-title":"Cancer Treat Rev"},{"key":"10.3816\/CLM.2007.n.011_bib24","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0959-8049(98)00277-9","article-title":"Markers of bone resorption in patients treated with pamidronate","volume":"34","author":"Lipton","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.3816\/CLM.2007.n.011_bib25","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/clinchem\/41.10.1489","article-title":"Biochemical markers of bone turnover in patients with metastatic bone disease","volume":"41","author":"Demers","year":"1995","journal-title":"Clin Chem"},{"key":"10.3816\/CLM.2007.n.011_bib26","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/sj.bjc.6690506","article-title":"Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer","volume":"80","author":"Vinholes","year":"1999","journal-title":"Br J Cancer"},{"key":"10.3816\/CLM.2007.n.011_bib27","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/ctrv.2000.0213","article-title":"Markers of bone turnover in prostate cancer","volume":"27","author":"Garnero","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"10.3816\/CLM.2007.n.011_bib28","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1600-0609.1999.tb01906.x","article-title":"Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline\/creatinine (DPD) and serum ICTP, and an evaluation of the DPD\/osteocalcin and ICTP\/osteocalcin ratios","volume":"62","author":"Carlson","year":"1999","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLM.2007.n.011_bib29","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.n.011_bib30","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1046\/j.1365-2141.2000.01960.x","article-title":"Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients","volume":"109","author":"Fonseca","year":"2000","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2007.n.011_bib31","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1365-2141.2003.04050.x","article-title":"Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy","volume":"120","author":"Abildgaard","year":"2003","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2007.n.011_bib32","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1038\/sj.leu.2403423","article-title":"Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL\/osteoprotegerin ratio in patients with multiple myeloma","volume":"18","author":"Terpos","year":"2004","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2007.n.011_bib33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0009-8981(02)00246-2","article-title":"Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients","volume":"325","author":"Alexandrakis","year":"2002","journal-title":"Clin Chim Acta"},{"key":"10.3816\/CLM.2007.n.011_bib34","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0046-8177(79)80094-5","article-title":"Acid phosphatase: new developments","volume":"10","author":"Romas","year":"1979","journal-title":"Hum Pathol"},{"key":"10.3816\/CLM.2007.n.011_bib35","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/0002-9343(74)90630-5","article-title":"Clinical significance of the human acid phosphatases: a review","volume":"56","author":"Yam","year":"1974","journal-title":"Am J Med"},{"key":"10.3816\/CLM.2007.n.011_bib36","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/clinchem\/33.4.458","article-title":"Characterization and assay of tartrate-resistant acid phosphatase activity in serum: potential use to assess bone resorption","volume":"33","author":"Lau","year":"1987","journal-title":"Clin Chem"},{"key":"10.3816\/CLM.2007.n.011_bib37","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3109\/00365519109104560","article-title":"Clinical usefulness of serum tartrate-resistant acid phosphatase activity determination to evaluate bone turnover","volume":"51","author":"Scarnecchia","year":"1991","journal-title":"Scand J Clin Lab Invest"},{"key":"10.3816\/CLM.2007.n.011_bib38","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1006\/bbrc.2000.2569","article-title":"Breast cancer cell line MDA-231 stimulates osteoclastogenesis and bone resorption in human osteoclasts","volume":"270","author":"Grano","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"10.3816\/CLM.2007.n.011_bib39","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ijc.11247","article-title":"Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma","volume":"106","author":"Terpos","year":"2003","journal-title":"Int J Cancer"},{"key":"10.3816\/CLM.2007.n.011_bib40","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1093\/clinchem\/38.12.2486","article-title":"Perspectives in alkaline phosphatase research","volume":"38","author":"Moss","year":"1992","journal-title":"Clin Chem"},{"key":"10.3816\/CLM.2007.n.011_bib41","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/clinchem\/45.8.1359","article-title":"Clinical utility of biochemical markers of bone remodeling","volume":"45","author":"Watts","year":"1999","journal-title":"Clin Chem"},{"key":"10.3816\/CLM.2007.n.011_bib42","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s002230010053","article-title":"Bone mineral density and biochemical markers of bone turnover in peri-and postmenopausal women","volume":"66","author":"De Leo","year":"2000","journal-title":"Calcif Tissue Int"},{"issue":"suppl 1","key":"10.3816\/CLM.2007.n.011_bib43","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/BF01621877","article-title":"The effect of age on bone collagen turnover as assessed by pyridinium crosslinks and procollagen I C-terminal peptide","volume":"3","author":"Eastell","year":"1993","journal-title":"Osteoporos Int"},{"key":"10.3816\/CLM.2007.n.011_bib44","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/ajcn\/61.3.514","article-title":"Calcium homeostasis and bone metabolism during pregnancy, lactation, and postweaning: a longitudinal study","volume":"61","author":"Cross","year":"1995","journal-title":"Am J Clin Nutr"},{"key":"10.3816\/CLM.2007.n.011_bib45","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2796.1992.tb00514.x","article-title":"Serum osteocalcin concentrations in patients with multiple myeloma\u2014correlation with disease stage and survival","volume":"231","author":"Carlson","year":"1992","journal-title":"J Intern Med"},{"key":"10.3816\/CLM.2007.n.011_bib46","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1600-0609.1996.tb00289.x","article-title":"Osteocalcin is not a marker of progress in multiple myeloma. Le Groupe d'Etude et de Recherche sur le Myelome (GERM)","volume":"56","author":"Mejjad","year":"1996","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLM.2007.n.011_bib47","first-page":"394","article-title":"Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients","volume":"86","author":"Corso","year":"2001","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2007.n.011_bib48","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1034\/j.1600-0609.2002.00505.x","article-title":"Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma","volume":"69","author":"Jakob","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLM.2007.n.011_bib49","first-page":"3047","article-title":"Serum levels of carboxy-terminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography","volume":"9","author":"Jakob","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2007.n.011_bib50","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00277-004-0937-9","article-title":"Prognostic value of urinary pyridinium crosslinks and their derivatives in multiple myeloma","volume":"84","author":"Samani","year":"2005","journal-title":"Ann Hematol"},{"key":"10.3816\/CLM.2007.n.011_bib51","first-page":"501","article-title":"Clinical studies using measurement of N-telopeptides of type 1 collagen (NTx) in patients with bone metastasis\u2014comparison with bone scintigraphy and other metabolic bone markers [in Japanese]","volume":"32","author":"Yamamoto","year":"1995","journal-title":"Kaku Igaku"},{"key":"10.3816\/CLM.2007.n.011_bib52","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1034\/j.1600-0609.2000.90074.x","article-title":"Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma","volume":"64","author":"Abildgaard","year":"2000","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLM.2007.n.011_bib53","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","article-title":"Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index","volume":"102","author":"Terpos","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.n.011_bib54","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.2002.06.037","article-title":"American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma","volume":"20","author":"Berenson","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.n.011_bib55","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/bcr414","article-title":"Development of bisphosphonates","volume":"4","author":"Fleisch","year":"2002","journal-title":"Breast Cancer Res"},{"key":"10.3816\/CLM.2007.n.011_bib56","first-page":"478","article-title":"A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases","volume":"7","author":"Berenson","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2007.n.011_bib57","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1023\/A:1012506426440","article-title":"Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease","volume":"12","author":"Jagdev","year":"2001","journal-title":"Ann Oncol"},{"issue":"suppl 3","key":"10.3816\/CLM.2007.n.011_bib58","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ctrv.2005.09.004","article-title":"Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence","volume":"31","author":"Smith","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"10.3816\/CLM.2007.n.011_bib59","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group","volume":"16","author":"Berenson","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.n.011_bib60","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, doubleblind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"10.3816\/CLM.2007.n.011_bib61","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1034\/j.1600-0609.2003.02823.x","article-title":"Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma","volume":"70","author":"Terpos","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLM.2007.n.011_bib62","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/sj.leu.2403890","article-title":"The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory\/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL\/osteoprotegerin ratio","volume":"19","author":"Terpos","year":"2005","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2007.n.011_bib63","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1034\/j.1600-0609.2000.065005331.x","article-title":"Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma","volume":"65","author":"Terpos","year":"2000","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLM.2007.n.011_bib64","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.2002.02.032","article-title":"Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma","volume":"20","author":"Menssen","year":"2002","journal-title":"J Clin Oncol"},{"issue":"16 suppl","key":"10.3816\/CLM.2007.n.011_bib65","first-page":"11s","article-title":"Suppression of bone turnover markers by zoledronic acid and correlation with clinical outcome","volume":"23","author":"Lipton","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.n.011_bib66","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CLM.2007.n.011_bib67","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.3816\/CLM.2007.n.011_bib68","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"issue":"suppl 9","key":"10.3816\/CLM.2007.n.011_bib69","first-page":"ix254","article-title":"Prognostic significance of persistently elevated N-telopeptide levels in patients with bone metastases from solid tumors","volume":"17","author":"Lipton","year":"2006","journal-title":"Ann Oncol"},{"issue":"suppl 9","key":"10.3816\/CLM.2007.n.011_bib70","first-page":"ix221","article-title":"Zoledronic acid may improve survival in lung cancer patients with high baseline bone marker levels","volume":"17","author":"Major","year":"2006","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2007.n.011_bib71","doi-asserted-by":"crossref","unstructured":"Berenson J, Shirina N, Chen Y-M. Zoledronic acid is associated with a survival benefit in patients with multiple myeloma stratified by baseline bone alkaline phosphatase levels. Presented at: MASCC\/ISOO 18th International Symposium; June 22-24, 2006; Toronto, Ontario, Canada. Abstract #1621.","DOI":"10.1200\/jco.2006.24.18_suppl.7505"},{"issue":"18 suppl","key":"10.3816\/CLM.2007.n.011_bib72","first-page":"423s","article-title":"Survival in patients with multiple myeloma receiving zoledronic acid: stratification by baseline bone alkaline phosphatase levels","volume":"24","author":"Berenson","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011700713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011700713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T07:51:07Z","timestamp":1631778667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011700713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":72,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S1557919011700713"],"URL":"https:\/\/doi.org\/10.3816\/clm.2007.n.011","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}